Skip to content

Lacerta and Prevail, A Wholly Owned Subsidiary of Lilly, Sign Agreement

Lacerta and Prevail, A Wholly Owned Subsidiary of Lilly, Sign Agreement to Develop Novel AAV Capsids for CNS Disorders

https://www.businesswire.com/news/home/20220823005289/en/Lacerta-and-Prevail-A-Wholly-Owned-Subsidiary-of-Lilly-Sign-Agreement-to-Develop-Novel-AAV-Capsids-for-CNS-Disorders

PrevPreviousLacerta Therapeutics Expands Executive Leadership Team
Recent Posts
  • Lacerta and Prevail, A Wholly Owned Subsidiary of Lilly, Sign Agreement
  • Lacerta Therapeutics Expands Executive Leadership Team
  • GrowFL Announces Lacerta Therapeutics as an Honoree: 11th Annual Florida Companies to Watch

We Would Like To Hear From You

Developing a constellation of gene-based therapies.

Charting a path to tomorrow’s health.

Website Map

  • Home
  • Programs
  • Technology
  • About Us
  • Careers
  • Contact
  • News

Contact Us

 (386) 518-6424

Lacerta Therapeutics
14189 NW 129th Way
Alachua, FL 32615
info@Lacertatx.com

News & Press Releases

Read our latest organizational news, press releases, and find out what is new in the industry. 

Read More

© 2021 All rights reserved

MADE WITH LIVEWIRE